Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials

Min Liu,Zhiyao Wang,Huifang Shang

DOI: https://doi.org/10.1007/s00415-024-12269-5

2024-03-15

Journal of Neurology

Abstract:Multiple system atrophy is a rare, debilitating, adult-onset neurodegenerative disorder that manifests clinically as a diverse combination of parkinsonism, cerebellar ataxia, and autonomic dysfunction. It is pathologically characterized by oligodendroglial cytoplasmic inclusions containing abnormally aggregated α-synuclein. According to the updated Movement Disorder Society diagnostic criteria for multiple system atrophy, the diagnosis of clinically established multiple system atrophy requires the manifestation of autonomic dysfunction in combination with poorly levo-dopa responsive parkinsonism and/or cerebellar syndrome. Although symptomatic management of multiple system atrophy can substantially improve quality of life, therapeutic benefits are often limited, ephemeral, and they fail to modify the disease progression and eradicate underlying causes. Consequently, effective breakthrough treatments that target the causes of disease are needed. Numerous preclinical and clinical studies are currently focusing on a set of hallmarks of neurodegenerative diseases to slow or halt the progression of multiple system atrophy: pathological protein aggregation, synaptic dysfunction, aberrant proteostasis, neuronal inflammation, and neuronal cell death. Meanwhile, specific biomarkers and measurements with higher specificity and sensitivity are being developed for the diagnosis of multiple system atrophy, particularly for early detection of the disease. More intriguingly, a growing number of new disease-modifying candidates, which can be used to design multi-targeted, personalized treatment in patients, are being investigated, notwithstanding the failure of most previous attempts.

clinical neurology

What problem does this paper attempt to address?

The paper primarily explores the research related to Multiple System Atrophy (MSA) and aims to address the following key issues:

1. **Disease Diagnosis and Biomarkers**:
- The paper emphasizes the updates in the current MSA diagnostic criteria and proposes higher sensitivity and specificity requirements. The new diagnostic criteria include four levels: neuropathological confirmation, clinical confirmation, clinically probable, and possible prodromal MSA.
- The research also explores various potential biomarkers, such as α-synuclein, neurofilament light chain (Nfl), total tau protein, etc., and points out that the detection of these biomarkers in body fluids may aid in early diagnosis.

2. **Pathological Mechanisms and Therapeutic Targets**:
- MSA is a rapidly progressing neurodegenerative disease characterized by the abnormal aggregation of α-synuclein in oligodendrocytes forming glial cytoplasmic inclusions (GCIs). The paper describes this process in detail and its impact on neurons.
- In response to the aggregation of α-synuclein, the research proposes various therapeutic strategies, including immunotherapy, inhibition of α-synuclein aggregation, and gene therapy.

3. **Progress in Clinical Trials**:
- Despite numerous clinical trials over the past few decades, most attempts have not been successful. The paper summarizes some of the ongoing or completed clinical trials, including active immunization, passive immunization, antisense oligonucleotides, and other therapeutic methods.
- A table presents the results of various clinical trials targeting different pathological markers, with some drugs having entered the clinical trial phase, though their efficacy remains to be verified.

In summary, the paper attempts to propose more effective diagnostic methods and therapeutic strategies by comprehensively analyzing the pathological mechanisms, diagnostic criteria, and treatment progress of MSA to address this rapidly progressing and difficult-to-cure disease.